IL144315A0 - Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders - Google Patents

Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders

Info

Publication number
IL144315A0
IL144315A0 IL14431500A IL14431500A IL144315A0 IL 144315 A0 IL144315 A0 IL 144315A0 IL 14431500 A IL14431500 A IL 14431500A IL 14431500 A IL14431500 A IL 14431500A IL 144315 A0 IL144315 A0 IL 144315A0
Authority
IL
Israel
Prior art keywords
neurotrophin
analogues
methods
treatment
hypomotility disorders
Prior art date
Application number
IL14431500A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL144315A0 publication Critical patent/IL144315A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14431500A 1999-01-15 2000-01-11 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders IL144315A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/232,171 US6656474B1 (en) 1999-01-15 1999-01-15 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
PCT/US2000/000682 WO2000041719A1 (en) 1999-01-15 2000-01-11 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders

Publications (1)

Publication Number Publication Date
IL144315A0 true IL144315A0 (en) 2002-05-23

Family

ID=22872143

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14431500A IL144315A0 (en) 1999-01-15 2000-01-11 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
IL144315A IL144315A (en) 1999-01-15 2001-07-13 Use of a neurotrophin and its analogues for the preparation of a medicament for the treatment of gastrointestinal hypomotility disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL144315A IL144315A (en) 1999-01-15 2001-07-13 Use of a neurotrophin and its analogues for the preparation of a medicament for the treatment of gastrointestinal hypomotility disorders

Country Status (13)

Country Link
US (1) US6656474B1 (de)
EP (1) EP1146899B1 (de)
JP (1) JP4489303B2 (de)
AT (1) ATE345811T1 (de)
AU (1) AU775860B2 (de)
CA (1) CA2360252C (de)
DE (1) DE60031951D1 (de)
IL (2) IL144315A0 (de)
NO (1) NO329488B1 (de)
NZ (1) NZ512968A (de)
TR (2) TR200201875T2 (de)
WO (1) WO2000041719A1 (de)
ZA (1) ZA200105799B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
DK1292680T3 (da) * 2000-06-22 2010-03-08 Genentech Inc Agonist-anti-TrkC monoklonale antistoffer
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US20070014786A1 (en) * 2003-03-20 2007-01-18 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
PL3013353T3 (pl) 2013-06-26 2021-09-20 Xigen Inflammation Ltd. Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US5962404A (en) * 1989-08-28 1999-10-05 Yeda Research & Development Co., Ltd. Enzymatically-produced oligodendrocyte cytotoxic dimeric IL-2 factor
US6174701B1 (en) * 1989-12-12 2001-01-16 Genentech, Inc. Neuronal factor
AU4920893A (en) * 1992-09-14 1994-04-12 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
MX9604985A (es) 1994-04-25 1998-05-31 Genentech Inc Cardiotropina y usos de la misma.
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6211142B1 (en) 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
JP3540912B2 (ja) * 1997-03-28 2004-07-07 京セラ株式会社 釣糸用ガイド部材
WO1998049308A1 (en) 1997-04-25 1998-11-05 Genentech, Inc. Ngf variants
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor

Also Published As

Publication number Publication date
EP1146899B1 (de) 2006-11-22
NO20013493D0 (no) 2001-07-13
NZ512968A (en) 2003-09-26
TR200102767T2 (tr) 2002-04-22
WO2000041719A9 (en) 2001-08-30
EP1146899A4 (de) 2003-03-05
NO329488B1 (no) 2010-10-25
JP2002534479A (ja) 2002-10-15
CA2360252C (en) 2010-11-02
IL144315A (en) 2008-08-07
AU775860B2 (en) 2004-08-19
AU2963600A (en) 2000-08-01
TR200201875T2 (tr) 2002-09-23
ATE345811T1 (de) 2006-12-15
WO2000041719A1 (en) 2000-07-20
NO20013493L (no) 2001-09-17
US6656474B1 (en) 2003-12-02
EP1146899A1 (de) 2001-10-24
ZA200105799B (en) 2002-01-24
CA2360252A1 (en) 2000-07-20
DE60031951D1 (de) 2007-01-04
JP4489303B2 (ja) 2010-06-23

Similar Documents

Publication Publication Date Title
IL144315A0 (en) Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
EP1565644A4 (de) Verfahren und system zur behandlung von bohrlöchern
HK1133017A1 (en) Specific binding agents of human angiopoietin-2
ZA200001883B (en) Methods and apparatus for producing and treating novel elastomer composites.
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
MXPA01007451A (es) Porfirinas sustituidas.
ZA200108446B (en) Novel method of treatment.
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
DE69923044D1 (de) Gewebebehandlungsmittel, Gewebe, Textildruckverfahren sowie Druck
PL368948A1 (en) Process and composition for treating wood
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
DK1143917T3 (da) Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
SG121787A1 (en) Oil retention treatment agent, oil retention treatment method using the same, and watch having been oil retention treated by the oil retention treatment method
UA33439A (uk) Спосіб інтенсивного лікування шизофренії
UA33531A (uk) Спосіб терапії шизофренії
HK1058305A1 (en) Combinations of dalfopristine/quinupristine with cefpirome
UA32363A (uk) Спосіб лікування хронічного алкоголізму
UA32314A (uk) Спосіб лікування некротичного панкреатиту
UA32288A (uk) Спосіб лікування дегенеративних і запальних процесів
GB9704073D0 (en) Lyocell fabric treatment
GB0128432D0 (en) Fabric treatment process
UA36261A (uk) Спосіб лікування простої шизофренії з суїцидальною поведінкою
TW200635950A (en) Specific binding agents of human angiopoietin-2
UA32146A (uk) Спосіб оцінки ефективності лікування пародонтита
UA36251A (uk) Спосіб комплексної терапії простої шизофренії

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed